This finding of rapid enzyme cleavage prompted the development of two successful therapeutic strategies for T2DM: the use of DPP-4 resistant GLP-1 receptor agonists and DPP-4 inhibitors [3, 5]. Here, DPP4 is linked to type 2 diabetes mellitus.